506 IGNYTE: an open-label, multicenter, phase 1/2 (Ph 1/2) clinical trial of RP1 ± nivolumab in patients with advanced solid tumors
- Resource Type
- article
- Source
- Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
- Subject
Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 - Language
- English
- ISSN
- 2051-1426